688166 博瑞医药
已收盘 09-30 15:00:00
资讯
新帖
简况
博瑞医药：终止发行H股股票并在港交所主板上市
同花顺 · 09-30 16:58
博瑞医药：终止发行H股股票并在港交所主板上市
“药二代”密集走向台前，大多拥有海外名校背景，将如何接好“转型”这一棒？
红星资本局 · 09-22
“药二代”密集走向台前，大多拥有海外名校背景，将如何接好“转型”这一棒？
每周股票复盘：博瑞生物医药（688166）股东减持547.33万股致股本变动
证券之星 · 09-20
每周股票复盘：博瑞生物医药（688166）股东减持547.33万股致股本变动
9月17日博瑞医药发布公告，股东减持547.33万股
证券之星 · 09-17
9月17日博瑞医药发布公告，股东减持547.33万股
博瑞医药：硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司
证券之星 · 09-16
博瑞医药：硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司
每周股票复盘：博瑞医药（688166）将参加科创板业绩说明会
证券之星 · 09-13
每周股票复盘：博瑞医药（688166）将参加科创板业绩说明会
股市必读：博瑞医药新发布《关于参加2026年半年度科创板创新药行业集体业绩说明会的公告》
证券之星 · 09-09
股市必读：博瑞医药新发布《关于参加2026年半年度科创板创新药行业集体业绩说明会的公告》
9月7日博瑞医药涨7.07%，科创创新药ETF国泰基金重仓该股
证券之星 · 09-07
9月7日博瑞医药涨7.07%，科创创新药ETF国泰基金重仓该股
博瑞医药（688166）2026年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 09-01
博瑞医药（688166）2026年中报简析：营收净利润同比双双增长，应收账款上升
博瑞医药（688166）披露2026年半年度报告，8月31日股价上涨4.41%
证券之星 · 08-31
博瑞医药（688166）披露2026年半年度报告，8月31日股价上涨4.41%
博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%
智通财经 · 08-30
博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%
博瑞医药(688166)6月30日股东户数2.1万户，较上期增加2.94%
证券之星 · 08-30
博瑞医药(688166)6月30日股东户数2.1万户，较上期增加2.94%
每周股票复盘：博瑞医药（688166）BGM1812注射液减重效果显著
证券之星 · 08-09
每周股票复盘：博瑞医药（688166）BGM1812注射液减重效果显著
8月7日博瑞医药涨9.50%，科创创新药ETF国泰基金重仓该股
证券之星 · 08-07
8月7日博瑞医药涨9.50%，科创创新药ETF国泰基金重仓该股
博瑞医药（688166）披露BGM1812注射液减重适应症Ⅰ期临床试验数据，8月6日股价下跌2.44%
证券之星 · 08-06
博瑞医药（688166）披露BGM1812注射液减重适应症Ⅰ期临床试验数据，8月6日股价下跌2.44%
博瑞医药：BGM1812注射液减重适应症Ⅰ期临床试验取得积极结果
格隆汇 · 08-06
博瑞医药：BGM1812注射液减重适应症Ⅰ期临床试验取得积极结果
每周股票复盘：博瑞医药（688166）控股子公司获噻托溴铵吸入喷雾剂注册证
证券之星 · 08-02
每周股票复盘：博瑞医药（688166）控股子公司获噻托溴铵吸入喷雾剂注册证
博瑞医药(688166.SH)子公司获得噻托溴铵吸入喷雾剂药品注册证书
智通财经 · 07-31
博瑞医药(688166.SH)子公司获得噻托溴铵吸入喷雾剂药品注册证书
7月30日博瑞医药跌5.10%，科创创新药ETF国泰基金重仓该股
证券之星 · 07-30
7月30日博瑞医药跌5.10%，科创创新药ETF国泰基金重仓该股
每周股票复盘：博瑞医药（688166）获噻托溴铵奥达特罗吸入喷雾剂注册证
证券之星 · 07-26
每周股票复盘：博瑞医药（688166）获噻托溴铵奥达特罗吸入喷雾剂注册证
加载更多
公司概况
公司名称：
博瑞生物医药(苏州)股份有限公司
所属行业：
医药制造业
上市日期：
2019-11-08
主营业务：
博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是创新药BGM0504、BGM1812、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠、阿尼芬净、泊沙康唑、依维莫司、吡美莫司、布地奈德、沙美特罗替卡松、噻托溴铵、艾立布林、芦比替定。
发行价格：
12.71
{"stockData":{"symbol":"688166","market":"SH","secType":"STK","nameCN":"博瑞医药","latestPrice":35.81,"timestamp":1790751600000,"preClose":34.36,"halted":0,"volume":12909438,"delay":0,"changeRate":0.0422,"floatShares":436000000,"shares":436000000,"eps":0.221,"marketStatus":"已收盘","change":1.45,"latestTime":"09-30 15:00:00","open":34.37,"high":36.55,"low":34.23,"amount":460000000,"amplitude":0.0675,"askPrice":35.81,"askSize":0,"bidPrice":35.8,"bidSize":142,"shortable":0,"etf":0,"ttmEps":0.221,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1791423000000},"marketStatusCode":5,"adr":0,"adjPreClose":34.36,"symbolType":"stock_kcb","openAndCloseTimeList":[[1790731800000,1790739000000],[1790744400000,1790751600000]],"highLimit":37.8,"lowLimit":30.92,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":435794991,"isCdr":false,"pbRate":5.11,"roa":"--","peRate":162.036199,"roe":"2.19%","epsLYR":0.13,"committee":0.732726,"marketValue":15606000000,"turnoverRate":0.0296,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-10-08。","afterMarket":{"amount":35810,"volume":1000,"close":35.81,"buyVolume":900,"sellVolume":0,"time":1790753637746,"indexStatus":"已收盘 09-30 15:30:00","preClose":34.36},"floatMarketCap":15606000000},"requestUrl":"/m/hq/s/688166","defaultTab":"news","newsList":[{"id":"2671127214","title":"博瑞医药：终止发行H股股票并在港交所主板上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2671127214","media":"同花顺","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2671127214?lang=zh_cn&edition=full","pubTime":"2026-09-30 16:58","pubTimestamp":1790758680,"startTime":"0","endTime":"0","summary":"9月30日，博瑞医药(688166.SH)公告称，公司此前曾审议通过发行H股股票并在香港联交所主板上市的相关议案，鉴于前次申报将于近日到期，结合自身实际情况及境内外资本市场环境变化等因素，经 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260930/c680414474.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260930/c680414474.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669234144","title":"“药二代”密集走向台前，大多拥有海外名校背景，将如何接好“转型”这一棒？","url":"https://stock-news.laohu8.com/highlight/detail?id=2669234144","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669234144?lang=zh_cn&edition=full","pubTime":"2026-09-22 20:16","pubTimestamp":1790079360,"startTime":"0","endTime":"0","summary":"红星资本局注意到，“药二代”们正密集走向台前。与“创一代”不同的是，他们大多拥有海外名校背景，进入核心管理层的方式也各不相同。今年以来，还有多位“药二代”走向台前。多家药企处于业务转型期二代接棒或面临考验值得一提的是，近期迎来“药二代”上台的上市公司，多数处于业务转型期。“药二代”走向前台，企业如何完成转型，仍有待时间验证。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-09-22/doc-inistexc1956967.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0880133367.SGD","BK1191","IE00BZ08YR35.GBP","LU1008478684.HKD","LU1226288170.HKD","LU1226287529.USD","LU1152091168.USD","688166","LU1807302812.USD","BK0046","BK0114","IE00BZ08YT58.USD","300298","BK0187","IE00BZ08YS42.EUR","LU1951186391.HKD","LU1328277881.USD","BK1521","HK0000165453.HKD","LU0315179316.USD","BK0102","LU1813983027.USD","IE00B543WZ88.USD","LU2039709279.SGD","01093","LU1960683339.HKD","300453","BK0028","LU0067412154.USD","LU0072913022.USD","KURE","LU1226287792.SGD","SG9999004220.SGD","LU1152091754.HKD","LU1226287875.USD","LU0314109678.HKD","IE0008368742.USD","IE0008369823.USD","LU1993786604.SGD","000513","LU0326950275.SGD","LU1226288253.USD","IE00B031HY20.USD","LU0140636845.USD","BK0239","600380","BK0251","BK0188","BK0077","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668906916","title":"每周股票复盘：博瑞生物医药（688166）股东减持547.33万股致股本变动","url":"https://stock-news.laohu8.com/highlight/detail?id=2668906916","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668906916?lang=zh_cn&edition=full","pubTime":"2026-09-20 01:07","pubTimestamp":1789837632,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，博瑞生物医药报收于35.03元，较上周的35.23元下跌0.57%。本周，博瑞生物医药9月18日盘中最高价报36.15元。博瑞生物医药当前最新总市值152.66亿元，在化学制药板块市值排名27/149，在两市A股市值排名1261/5220。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166","161726","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668921965","title":"9月17日博瑞医药发布公告，股东减持547.33万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2668921965","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668921965?lang=zh_cn&edition=full","pubTime":"2026-09-17 18:01","pubTimestamp":1789639263,"startTime":"0","endTime":"0","summary":"证券之星消息，9月17日博瑞医药发布公告《博瑞医药:股东减持股份结果公告》，其股东先进制造产业投资基金(有限合伙)于2026年6月18日至2026年9月17日间合计减持547.33万股，占公司目前总股本的1.2559%，变动期间该股股价下跌14.31%，截止9月17日收盘报34.6元。股东增减持详情见下表：根据博瑞医药2026年中报公布的十大股东详情如下：本文数据来源于博瑞医药公告，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091700029781.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667602583","title":"博瑞医药：硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2667602583","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667602583?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:12","pubTimestamp":1789553530,"startTime":"0","endTime":"0","summary":"证券之星消息，博瑞医药(688166)09月16日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘：贵公司的硫酸阿托品滴眼液的临床是暂停了吗？大约何时能出临床数据？博瑞医药回复：尊敬的投资者您好！公司2022年年度报告披露，硫酸阿托品滴眼液取得了药物临床试验批准通知书，且公司已将硫酸阿托品滴眼液的《药物临床试验批准通知书》转让给宁波视方医药科技有限公司。感谢您的关注，谢谢！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091600029004.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","688166","BK0239","BK1574","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667550030","title":"每周股票复盘：博瑞医药（688166）将参加科创板业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2667550030","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667550030?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:09","pubTimestamp":1789240151,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，博瑞医药报收于35.23元，较上周的34.79元上涨1.26%。本周，博瑞医药9月8日盘中最高价报39.26元。本周关注点来自公司公告汇总：博瑞医药将参加2026年半年度科创板创新药行业集体业绩说明会。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000929.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666374138","title":"股市必读：博瑞医药新发布《关于参加2026年半年度科创板创新药行业集体业绩说明会的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2666374138","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666374138?lang=zh_cn&edition=full","pubTime":"2026-09-09 00:50","pubTimestamp":1788886225,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，博瑞医药报收于37.91元，上涨1.77%，换手率3.15%，成交量13.71万手，成交额5.19亿元。公司公告汇总：博瑞医药将于9月16日15:00–17:00参加上交所主办的科创板创新药行业集体业绩说明会，董事长、总经理袁建栋等高管将出席并接受网络文字互动提问。董事长、总经理袁建栋，财务总监詹春雷，独立董事许冬冬，董事会秘书李加宁将出席。投资者可于9月9日至9月15日16:00前通过上证路演中心或公司邮箱IR@bright-gene.com提前提问。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090900002007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1161","688166","159992","BK1574","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665316080","title":"9月7日博瑞医药涨7.07%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665316080","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665316080?lang=zh_cn&edition=full","pubTime":"2026-09-07 16:38","pubTimestamp":1788770331,"startTime":"0","endTime":"0","summary":"证券之星消息，9月7日博瑞医药涨7.07%，收盘报37.25元，换手率3.65%，成交量15.9万手，成交额5.81亿元。重仓博瑞医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700021114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["589720","BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664885269","title":"博瑞医药（688166）2026年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2664885269","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664885269?lang=zh_cn&edition=full","pubTime":"2026-09-01 06:09","pubTimestamp":1788214181,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期博瑞医药发布2026年中报。截至本报告期末，公司营业总收入6.78亿元，同比上升26.17%，归母净利润5893.28万元，同比上升243.17%。按单季度数据看，第二季度营业总收入3.53亿元，同比上升22.42%，第二季度归母净利润4963.91万元，同比上升1078.12%。本报告期博瑞医药应收账款上升，应收账款同比增幅达50.25%。最近有知名机构关注了公司以下问题：问：答环节答：二、问环节本文数据来源于博瑞医药2026年中报，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100004809.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079789","title":"博瑞医药（688166）披露2026年半年度报告，8月31日股价上涨4.41%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079789","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663079789?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:43","pubTimestamp":1788169412,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，博瑞医药报收于36.24元，较前一交易日上涨4.41%，最新总市值为157.93亿元。该股当日开盘36.34元，最高36.5元，最低34.91元，成交额达5.2亿元，换手率为3.34%。博瑞生物医药（苏州）股份有限公司于2026年8月31日披露《2026年半年度报告》。公告显示，截至报告期末，公司总资产为6,505,278,933.66元，较上年度末增长11.68%；归属于上市公司股东的净资产为3,052,325,774.52元，较上年度末增长21.07%。经营活动产生的现金流量净额为15,229,433.59元，同比减少86.60%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024619.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663704907","title":"博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663704907","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663704907?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:44","pubTimestamp":1788083092,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药 发布2026年半年度报告，报告期内，公司实现营业收入6.78亿元，同比增长26.17%。实现归属于上市公司股东的净利润5893.28万元，同比增长243.17%。主要系营业收入增长带来毛利额同比增长，营业收入的增长部分主要集中在高毛利产品上，导致整体利润上升明显。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489023.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"博瑞医药(688166.SH)发布上半年业绩，归母净利润5893.28万元，同比增长243.17%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663491070","title":"博瑞医药(688166)6月30日股东户数2.1万户，较上期增加2.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663491070","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663491070?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080863,"startTime":"0","endTime":"0","summary":"证券之星消息，近日博瑞医药披露，截至2026年6月30日公司股东户数为2.1万户，较3月31日增加599.0户，增幅为2.94%。在化学制药行业个股中，博瑞医药股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.67万户。从股价来看，2026年3月31日至2026年6月30日，博瑞医药区间跌幅为27.74%，在此期间股东户数增加599.0户，增幅为2.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658673621","title":"每周股票复盘：博瑞医药（688166）BGM1812注射液减重效果显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2658673621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658673621?lang=zh_cn&edition=full","pubTime":"2026-08-09 01:19","pubTimestamp":1786209550,"startTime":"0","endTime":"0","summary":"截至2026年8月7日收盘，博瑞医药报收于38.14元，较上周的32.94元上涨15.79%。本周，博瑞医药8月7日盘中最高价报38.45元。本周关注点公司公告汇总：BGM1812注射液Ⅰ期临床试验显示体重较基线平均降低1.9%~9.2%公司公告汇总：BGM1812注射液安全性良好，支持进入Ⅱ期临床研究公司公告汇总：部分剂量组体重下降≥5%的受试者比例达70.0%~85.7%公司公告汇总博瑞医药自主研发的BGM1812注射液在中国和美国开展的I期临床试验取得积极结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080900000139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616397","title":"8月7日博瑞医药涨9.50%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616397","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616397?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:40","pubTimestamp":1786092005,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日博瑞医药涨9.50%，收盘报38.14元，换手率7.0%，成交量30.51万手，成交额11.29亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.8765，较上一交易日下跌0.33%，近一年下跌13.36%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700027981.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["589720","688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657963008","title":"博瑞医药（688166）披露BGM1812注射液减重适应症Ⅰ期临床试验数据，8月6日股价下跌2.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2657963008","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657963008?lang=zh_cn&edition=full","pubTime":"2026-08-06 22:28","pubTimestamp":1786026499,"startTime":"0","endTime":"0","summary":"截至2026年8月6日收盘，博瑞医药报收于34.83元，较前一交易日下跌2.44%，最新总市值为151.79亿元。该股当日开盘36.4元，最高36.65元，最低34.7元，成交额达6.86亿元，换手率为4.45%。近日，博瑞医药披露关于BGM1812注射液减重适应症Ⅰ期临床试验数据的公告。公告显示，博瑞医药自主研发的BGM1812注射液在中国和美国开展的I期临床试验取得积极结果。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600039999.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657843906","title":"博瑞医药：BGM1812注射液减重适应症Ⅰ期临床试验取得积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2657843906","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657843906?lang=zh_cn&edition=full","pubTime":"2026-08-06 17:59","pubTimestamp":1786010350,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656877316","title":"每周股票复盘：博瑞医药（688166）控股子公司获噻托溴铵吸入喷雾剂注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2656877316","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656877316?lang=zh_cn&edition=full","pubTime":"2026-08-02 01:28","pubTimestamp":1785605291,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，博瑞医药报收于32.94元，较上周的34.81元下跌5.37%。本周，博瑞医药7月28日盘中最高价报36.59元。本周关注点公司公告汇总：控股子公司艾特美获噻托溴铵吸入喷雾剂药品注册证书，为国内首家获批该仿制药企业。公司公告汇总博瑞医药控股子公司艾特美（苏州）医药科技有限公司近日收到国家药品监督管理局签发的噻托溴铵吸入喷雾剂《药品注册证书》，批准其上市。药品批准文号有效期至2031年7月27日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080200000209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655355321","title":"博瑞医药(688166.SH)子公司获得噻托溴铵吸入喷雾剂药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2655355321","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655355321?lang=zh_cn&edition=full","pubTime":"2026-07-31 15:51","pubTimestamp":1785484287,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博瑞医药 发布公告，近日，公司控股子公司艾特美(苏州)医药科技有限公司收到国家药品监督管理局签发的“噻托溴铵吸入喷雾剂”《药品注册证书》。噻托溴铵吸入喷雾剂原研厂家为勃林格殷格翰，目前市场流通药品仅有原研进口品种。据统计，噻托溴铵吸入喷雾剂2023年全球销售额为18.42亿美元，2024年全球销售额为17.70亿美元，2025年全球销售额为16.70亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"博瑞医药(688166.SH)子公司获得噻托溴铵吸入喷雾剂药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688166","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655824508","title":"7月30日博瑞医药跌5.10%，科创创新药ETF国泰基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655824508","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655824508?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:38","pubTimestamp":1785400734,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日博瑞医药跌5.10%，收盘报31.83元，换手率3.35%，成交量14.59万手，成交额4.74亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为国泰基金的科创创新药ETF国泰。科创创新药ETF国泰目前规模为21.97亿元，最新净值0.8945，较上一交易日上涨1.22%，近一年下跌10.33%。科创创新药ETF国泰的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000025907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688166","589720","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654937052","title":"每周股票复盘：博瑞医药（688166）获噻托溴铵奥达特罗吸入喷雾剂注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2654937052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654937052?lang=zh_cn&edition=full","pubTime":"2026-07-26 01:20","pubTimestamp":1785000020,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘，博瑞医药报收于34.81元，较上周的38.48元下跌9.54%。交易信息汇总7月22日博瑞医药发生1笔大宗交易，折价29.29%，合计成交575.44万元。博瑞医药控股子公司艾特美（苏州）医药科技有限公司近日收到国家药品监督管理局签发的噻托溴铵奥达特罗吸入喷雾剂《药品注册证书》，该药品适用于慢性阻塞性肺疾病患者的长期维持治疗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072600000166.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688166"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1790867578899,"stockEarnings":[{"period":"1week","weight":-0.0135},{"period":"1month","weight":-0.0119},{"period":"3month","weight":0.0848},{"period":"6month","weight":-0.3286},{"period":"1year","weight":-0.4009},{"period":"ytd","weight":-0.2698}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0362},{"period":"3month","weight":-0.0463},{"period":"6month","weight":-0.0098},{"period":"1year","weight":-0.0105},{"period":"ytd","weight":-0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"博瑞生物医药(苏州)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"20963人(较上一季度增加2.94%)","perCapita":"20788股","listingDate":"2019-11-08","address":"江苏省苏州市吴中区工业园区星湖街218号纳米科技园C25栋","registeredCapital":"43579万元","survey":" 博瑞生物医药(苏州)股份有限公司的主营业务是医药中间体、原料药和制剂产品的研发、生产。公司的主要产品是创新药BGM0504、BGM1812、恩替卡韦、奥司他韦、卡泊芬净、米卡芬净钠、阿尼芬净、泊沙康唑、依维莫司、吡美莫司、布地奈德、沙美特罗替卡松、噻托溴铵、艾立布林、芦比替定。","listedPrice":12.71},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"博瑞医药,688166,博瑞医药股票,博瑞医药股票老虎,博瑞医药股票老虎国际,博瑞医药行情,博瑞医药股票行情,博瑞医药股价,博瑞医药股市,博瑞医药股票价格,博瑞医药股票交易,博瑞医药股票购买,博瑞医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"博瑞医药(688166)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供博瑞医药(688166)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}